Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRD3874 in Relapsed/Refractory Acute Myeloid Leukemia
NCT06626633Phase 1Suspended
- Sponsor
- University of Maryland, Baltimore
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CRD3874 in acute myeloid leukemia (AML), sponsored by University of Maryland, Baltimore. Primary endpoints: Safety and Tolerability by multiplex cytokine profiling at 2 years, Safety and Tolerability by qPCR at 2 years and 2 more. Started Aug 2024; status: suspended.
02
Drugs
CRD3874
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06626633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06626633.